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was designed to evaluate long-term vascular biology response to fluorocopolymer
(poly-vinylidene fluoride hexafluoroproprylene, PVDF-HFP) coated self-expandable
low-dose paclitaxel-eluting nitinol stent (FP-PES, 0.167g/mm2) in a porcine ilio-
femoral artery model.
Methods: FP-PES (6, 7 or 8mm x 80 mm, n12 at 30 and 180d, n13 at 90d) or BMS
(n12 at 30, 90 and 180d) with identical stent length and size were implanted in the
ilio-femoral arteries of 37 pigs. Complete histomorphometric and histopathologic analy-
ses were performed after termination of animals. In addition, an in vivo pharmacokinetic
(PK) study was conducted for FP-PES (n8/time-point) at 4, 10, 30, 60, 90 and 180d.
Paclitaxel levels in systemic blood and major organs were also evaluated.
Results: Paclitaxel released steadily without burst phenomenon. Paclitaxel levels were
below quantifiable levels in both blood and major organs at all-time points. Neointimal
thickness was significantly inhibited by FP-PES (0.350.09, 0.550.15 mm) compared
to BMS (0.700.25, 1.000.25 mm) at 30 and 90d (p0.001, respectively), yielding
reductions of in-stent stenosis by 48.1% and 51.9% for FP-PES versus BMS (P0.005
and 0.0001, respectively). No difference in any of the histomorphometric parameters
was apparent at 180d. Stents from both groups were completely re-endothelialized and
there was no thrombus apparent in either group at any time point., Drug effect was
observed as higher expression for both fibrin deposition and para-strut inflammation
scores in FP-PES vs. BMS (p0.05) at all time-points although the absolute scores were
low for both groups.
Conclusions: Maintaining long-term patency after peripheral endovascular therapy
remains a challenge. The FP-PES decreased neointimal formation at 30d and 90d
compared to BMS, with a comparable vascular healing response and no evidence of
systemic paclitaxel.
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Background: Little data are available regarding the association between the site of the
leg wound occurring from critical limb ischemia (CLI) and the prognosis of hemodialysis
patients with CLI after isolated infrapopliteal balloon angioplasty(BA).
Methods: This study used data obtained from a multi-center retrospective study.Among
serial 884 CLI patients who underwent BA for primary treatment of isolated infrapopliteal
lesions from 2004 to 2011, subjects were 449 serial patients on hemodialysis with a CLI
wound (ulcer or gangrene). The site of the CLI wound was observed before the initial
treatment and all wounds were confirmed to be either confined distal from the
metatarsals-phalanx(MP) joint to the tips of the toes or proximal from the MP joint to the
ankle. Patients with wounds confined distal to the MP joint were defined as the Distal(D)
group (109 patients, 109 limbs, age: 66.510.4 years) and those whose wounds were not
confined here were defined the Proximal(P) group (340 patients, 340 limbs, age: 69.29.6
years). The two groups were compared for average 3.01.5 years clinical outcomes.
Results: There was no significant difference in the percentage of patients with diabetes
mellitus (75.2 vs. 76.5%), contralateral CLI limb (23.9 vs. 21.5%), or coronary artery
disease (57.8vs. 58.2%). For the target vessel, there was no significant difference in the
ratio of target vessels with total occlusion (69.9 vs. 70.0%).The percentage of getting
direct flow to wounds site based on the angiosome concept was lower in P group than that
of D group (P:45.9 vs. D:63.5%, P0.01). At the 3-year clinical results, the P group had
high rates of major amputation (P:21.2 vs. D:12.3%, P0.05), while there was no
difference in the percentage of death (39.4% vs. 31.4%). The P group had a significantly
lower major amputation-free survival rate estimated using the Kaplan-Meier methods
compared to D group (P: 31.0 vs. D: 45.6%, Logrank; p0.01).
Conclusions: The limb salvage rate of hemodialysis patients after isolated infrapopliteal
BA whose CLI wounds were confined distal to the MP joint was better than that of
patients who had wounds proximal to the MP joint, but the mortality of all hemodyalisis
patents with CLI wounds was high.
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Background: Primary stenting from common iliac artery (CIA) to external iliac artery
(EIA), jailing internal iliac artery (IIA), has a risk of compromised IIA.The purpose of this
study was to evaluate in-hospital and 12 month clinical outcome in patients treated with
stent deployment at EIA-IIA bifurcation, especially in comparison between crossover
stenting strategy and non-crossover stenting one, focusing on fate of jailed IIA.
Methods: A retrospective study was performed of patients who underwent endovascular
intervention for iliac artery presented from February 2000 to April 2011. Subject was 60
patients/57 lesion with iliac arteries who underwent attempted recanalization with the
self-expandable or balloon expandable stent. And we divided these subjects into the two
following groups; 44 patients (45 lesions) treated with Crossover stenting with jailed of
IIA and 13 patients (15 lesions) underwent non-crossover stenting without coverage of
IIA. We have investigated patients background/lesion background/Bifurcation type/EVT
strategy/Clinical outcome/acute and chronic occlusion rate of IIA.
Results: No significant difference was detected in the baseline demographic, angio-
graphic, and lesion characteristics. Technical success obtained 100% .Regarding acute or
12 months occlusion rate of IIA, no difference was seen between Cross-over group and
Non-cross-over goup(acute: 4% vs 0%,12-month :4% vs 0%.
Conclusions: Occlusion rate of internal iliac(IIA) were extremely low and complains of
pelvic organ ischemia were not seen when treated with either crossover or non-crossover
stenting, for IIA in acute phase as well as 12 month.
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Background: Chronic total occlusions (CTO) of the SFA are a challenging subset of
lesions encountered in peripheral interventions. CTO’s of the SFA are commonly crossed
either with an intraluminal (IL) or re-entry device assisted subinitimal (SI) approach
followed by stenting. Even though both these techniques have a high immediate
procedural success rate the long term outcomes of each approach are not well studied.
Methods: We studied 112 patients (144 limbs) with obstructive SFA disease treated with
nitinol self-expanding stents; there were 77 (53.5%) limbs with CTO. We analyzed
in-stent restenosis (ISR) rates, as well as: age, sex, GFR, presence of diabetes and
coronary artery disease, lesion lengths, TASC Classification, and stent diameter in 3
subgroups of patients: without CTO; with CTO crossed IL; and with CTO crossed SI.
Results: In CTO group, 22 (28%) limbs were treated with SI approach, and 55 (72%)
using IL. During mean follow up period of 27.6 17 months, ISR was diagnosed in: 21
(31.3%) pts of non-CTO; 20 (36.4%) of IL CTO; and 13 (59.1%) of SI CTO, Figure 1.
The number of pts with diabetes was (p0.001) higher in CTO IL compared to CTO SI
group, 73.8% versus 26% respectively. The mean lesion length was 206.4 110 mm in
IL and 245.9  118 mm (p0.17) in SI. There was no significant difference in other
parameters.
Conclusions: We observed similar SFA ISR rates between pts without and with CTO if
CTO was crossed using IL approach. Device assisted SI approach in CTO pts was
associated with higher ISR compared to non-CTO pts and trend to higher ISR compared
to CTO IL group.
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Background: Interim analysis of the first 1000 patients treated with Misago RX nitinol
stent in iliac and femoropopliteal arteries at 1 year follow-up.
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Methods: e-MISAGO enrolled more than 3000 patients treated with the Misago stent in
94 European centers. All clinical data collected through an EDC platform are fully
monitored and all reported serious adverse events are independently adjudicated. Primary
safety (at 30 days) and efficacy endpoint (at 1 year) match the VIVA criteria.
Results: Patients (68% male) were 6710 years old, 63% were smokers, 36% had
diabetes mellitus (36% IDDM), 46% had hypercholesterolemia and 76% arterial hyper-
tension. Patients had history of previous coronary artery disease in 32% of the cases and
14% previous myocardial infarction. Claudication and symptomatic ischemia concerned
99% and 96% of the patient population. Mean lesion length was 64.559.0 mm, with
reference vessel diameter 6.31.3 mm. Mean lesions’ stenosis was 88.612.4% and
43.3% of the lesions were totally occluded. On average 1.20.5 vessels per patient were
treated with 1.20.45 stents per lesion. At baseline mean ABI was 0.590.22 and mean
Rutherford score was 2.511.31. At 12 months ABI improved in 81% patients and the
mean increased to 0.850.24; Rutherford score improved in 76% patients with mean
value of 0.721.16. The overall composite adverse events rate of death, amputation, and
revascularization was 9.7%.
Conclusions: The interim results from the e-MISAGO registry indicate promising device
performance of the Misago RX nitinol stent at 1 year.
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Background: The impact of vascular injury on drug transfer and vessel healing
following Paclitaxel Coated Balloon (PCB) use has not been described. We hypothesized
that the vessel uptake of paclitaxel and its resulting effect on healing is highly influenced
by the degree of mechanical injury exerted to the vessel wall following balloon inflation.
Methods: A total of 19 PCB (Cotavance, Medrad, Inc. Indianola, PA) were inflated in the
iliofemoral territory of 8 domestic swine targeting a 1.2:1 balloon to artery ratio (BAR).
All arteries were harvested at either 14 (n9) or 30 (n10) days for the evaluation of
tissue paclitaxel levels and histology. Based on the histological injury scores, all vessel
segments were classified into IEL ruptured (IEL-R) or IEL non-ruptured (IEL-NR).
Results: A total of 19 iliofemoral arteries were included in the analysis. The IEL-R group
had a higher BAR (1.440.08) compared to the IEL-NR (1.340.11, p0.1). At 14 days,
the median concentration of paclitaxel in the IEL-R group (1,251g/g) was higher than in
the IEL-NR group (465 g/g, p0.13). However, the% area of stenosis was comparable
among both groups at 14 and 30 days (see table). At 30 days, Paclitaxel tissue levels were
comparable among both groups. Fibrin and inflammatory scores were consistently higher
in the IEL-R group compared to the IEL-NR group at both 14 and 30 days (see table).
Conclusions: The degree of mechanical injury induced by balloon dilatation seems to
influence short-term drug transfer and long-term vessel healing following PCB use. The
implications of these findings on clinical outcomes deserve further evaluation in the
human setting.
Follow
Up
IEL
Rupture
Balloon
to Artery
Ratio
Fibrin
Score
Mean
Inflammation
Score
Area
Stenosis
(%)
Median
Concentration
(g/g)
15
Days
Yes 1.44 
0.08
3.00 
0
1.25  0.5 5.34 
1.39
1251.00
No 1.34 
0.11
1.74 
1.15
0.74  0.45 5.78 
5.25
465.00
p value 0.10 0.001 0.13 0.75 0.13
30
Days
Yes 1.61 
0.26
1.78 
0.83
1.00  0.5 11.43 
4.46
79.60
No 1.39 
0.25
1.07 
1.27
0.67  0.49 16.71 
10.45
66.50
p value 0.06 0.11 0.13 0.10 0.06
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Background: Due to the mechanism of drug transfer, Paclitaxel coated balloons (PCB)
are thought to result in non-uniform inhibition of neointima. We sought to investigate the
pattern of neointima distribution along the stented and reference(edges) segments
following PCB dilatation as compared to POBA controls in a peripheral swine model.
Methods: 16 Iliofemoral arteries were injured with balloon overstretch followed by a
BMS deployment. At 14 days, the in-stent restenosis was treated with either a PCB
(Cotavance, Medrad Inc, PA) or an identical uncoated balloon (POBA). At 28 days
following balloon inflation, all segments were analyzed by QVA and OCT. The OCT
percent area stenosis (%AS) was analyzed every 2mm along the treated segment. Percent
diameter stenosis (%DS) was analyzed within 5mm proximal and distal to the stent
marker by QVA.
Results: The efficacy of PCB was demonstrated by the 43% reduction of%AS by OCT
(27.39% versus POBA: 4713%, p0.006). In the test for homogeneity of variances,
there was no significant longitudinal variation between segments treated with PCB
(p0.2) or POBA (p0.6, see figure). At follow up, POBA demonstrated a progression
in neointimal proliferation at distal (26.9% increase, p0.001) and proximal (8.0%
increase, p0.05) vessel reference segments. Conversely, PCB exhibited neointimal
regression in the distal (-7.7%, p0.05) and proximal (1.4%, p0.5) reference segments.
Conclusions: In vivo OCT analysis showed a homogeneous inhibition of neointimal
formation following paclitaxel delivery. In addition the use of PCB reduces neointimal
proliferation at the borders of the stent.
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Background: Drug-coated balloons (DCB) have emerged as a potential alternative in
treating PAD. This study aimed to evaluate the tissue concentrations and efficacy of using
the Freeway DCB in porcine peripheral arteries. Thus no further extrapolation from
coronary preclinical experiments is needed.
Methods: Measurements of tissue paclitaxel concentration at 1h, 1 day, 3 days and 9 days
after dilation of peripheral arteries with Freeway™ balloon (Paclitaxel-eluting DEB) for
1 or 2 min in a total of 92 porcine arteries. Inflation time dependent determination of the
paclitaxcel concentration in the blood plasma Inflation time dependent determination of
the remnant paclitaxel concentration on the inflated balloon Histological investigations in
a porcine post-overstretch injury (1.3:1 balloon/artery ratio) model after 2 min inflation of
Freeeway™ (Paclitaxel-eluting DEB) or conventional balloon Measurement of area
stenosis (%) Measurement of neointimal area (mm2)
Results: Tissue Ptx concentrations: 1 hour post 238  molar at 1 min, 502  molar at 2
min of inflation 1 day post 26  molar at 1 min, 129  molar at 2 min 3 days post 19 
molar at 1 min, 35  molar at 2 min 9 days post 4  molar at 1 min and, (still to come)
at 2 min Plasma concentrations: 1 hour post 0,6 ng/ml at 1 min, 2,3 ng/ml at 2 min
Remnant Paclitaxel on the balloon 28% after 1 min,19% after 2 min Post-overstretch
injury (1.3:1): Femoralis neointima area of 0,62 mm2 for DCB vs 1,51 mm2 for POBA
p0.05 Iliaca 0,62 mm2 for DCB vs 1,24 mm2 for POBA p0.05 Area stenosis:
Femoralis 12,5% for DCB vs. 35,9% for POBA p0.05 Iliaca 16% for DCB vs. 32,3%
for POBA p0.05
Conclusions: The new dataset for peripheral arteries from porcine preclinical experi-
ments shows paclitaxel tissue concentration comparable to coronary results one hour post
inflation after 1 minute of inflation of the DCB. After 2 minutes, the concentration in
tissue was approx. double. This effect holds true for later time points up to 9 days. Safety
has been established in plasma measurements, and efficacy was significant in both
Femoralis and Iliaca as compared to POBA after balloon overstretch.
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